315 related articles for article (PubMed ID: 8631017)
41. Absorption, distribution, metabolism and excretion of YM466, a novel factor Xa inhibitor, in rats.
Mano Y; Sonoda T; Nakamura E; Usui T; Kamimura H
Biopharm Drug Dispos; 2004 Sep; 25(6):253-60. PubMed ID: 15334624
[TBL] [Abstract][Full Text] [Related]
42. Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells.
Scala S; Dickstein B; Regis J; Szallasi Z; Blumberg PM; Bates SE
Clin Cancer Res; 1995 Dec; 1(12):1581-7. PubMed ID: 9815959
[TBL] [Abstract][Full Text] [Related]
43. Absorption and enterohepatic circulation of baicalin in rats.
Xing J; Chen X; Zhong D
Life Sci; 2005 Nov; 78(2):140-6. PubMed ID: 16107266
[TBL] [Abstract][Full Text] [Related]
44. Disposition and metabolism of carbovir in mice dosed intravenously or orally.
el Dareer SM; Tillery KF; Rose LM; Struck RF; Hill DL
Drug Metab Dispos; 1990; 18(6):842-5. PubMed ID: 1981526
[TBL] [Abstract][Full Text] [Related]
45. Murine pharmacokinetics and metabolism of penclomedine [3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine, NSC 338720].
Reid JM; Mathiesen DA; Benson LM; Kuffel MJ; Ames MM
Cancer Res; 1992 May; 52(10):2830-4. PubMed ID: 1581896
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3-dioxolane]platinum(II) in rats.
Cho YB; Kim DK; Kim KH; Miyamoto G
Arzneimittelforschung; 1996 Jun; 46(6):629-34. PubMed ID: 8767356
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics of aminomethylpropanol in rats following oral and a novel dermal study design.
Saghir SA; Clark AJ; McClymont EL; Staley JL
Food Chem Toxicol; 2008 Feb; 46(2):678-87. PubMed ID: 17961896
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid.
Rao GS; Ramesh S; Ahmad AH; Tripathi HC; Sharma LD; Malik JK
Vet J; 2002 Jan; 163(1):85-93. PubMed ID: 11749141
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
[TBL] [Abstract][Full Text] [Related]
50. Bryostatin-1 stimulates the transcription of cyclooxygenase-2: evidence for an activator protein-1-dependent mechanism.
De Lorenzo MS; Yamaguchi K; Subbaramaiah K; Dannenberg AJ
Clin Cancer Res; 2003 Oct; 9(13):5036-43. PubMed ID: 14581379
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules.
Aherne GW; Hardcastle A; Ward E; Dobinson D; Crompton T; Valenti M; Brunton L; Jackman AL
Clin Cancer Res; 2001 Sep; 7(9):2923-30. PubMed ID: 11555611
[TBL] [Abstract][Full Text] [Related]
52. Absorption, disposition kinetics, and metabolic pathways of cyclohexene oxide in the male Fischer 344 rat and female B6C3F1 mouse.
Sauer JM; Bao J; Smith RL; McClure TD; Mayersohn M; Pillai U; Cunningham ML; Sipes IG
Drug Metab Dispos; 1997 Mar; 25(3):371-8. PubMed ID: 9172957
[TBL] [Abstract][Full Text] [Related]
53. Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials.
Osman S; Luthra SK; Brady F; Hume SP; Brown G; Harte RJ; Matthews JC; Denny WA; Baguley BC; Jones T; Price PM
Cancer Res; 1997 Jun; 57(11):2172-80. PubMed ID: 9187117
[TBL] [Abstract][Full Text] [Related]
54. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Varterasian ML; Mohammad RM; Shurafa MS; Hulburd K; Pemberton PA; Rodriguez DH; Spadoni V; Eilender DS; Murgo A; Wall N; Dan M; Al-Katib AM
Clin Cancer Res; 2000 Mar; 6(3):825-8. PubMed ID: 10741703
[TBL] [Abstract][Full Text] [Related]
55. Metabolism of the new liposomal anticancer drug N4-octadecyl-1-beta-D-arabinofuranosylcytosine in mice.
Koller-Lucae SK; Suter MJ; Rentsch KM; Schott H; Schwendener RA
Drug Metab Dispos; 1999 Mar; 27(3):342-50. PubMed ID: 10064564
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics of the antiviral agent carbocyclic 3-deazaadenosine.
Coulombe RA; Huie JM; Sharma RP; Huggins JW
Drug Metab Dispos; 1993; 21(4):555-9. PubMed ID: 8104112
[TBL] [Abstract][Full Text] [Related]
57. Plasma pharmacokinetics and urinary excretion of the polyamine analogue 1, 19-bis(ethylamino)-5, 10, 15-triazanonadecane in CD2F1 mice.
Eiseman JL; Yuan ZM; Eddington ND; Sentz DL; Callery PS; Egorin MJ
Cancer Chemother Pharmacol; 1996; 38(1):13-20. PubMed ID: 8603446
[TBL] [Abstract][Full Text] [Related]
58. Absorption, distribution and excretion of 14C-pirenzepine in rats. Accumulation characteristics after multiple dose regimen.
Kobayashi S; Kyui S; Yoshida T; Nagakura A; Oiwa Y; Matsumura R; Kohei H
Arzneimittelforschung; 1981; 31(4):679-90. PubMed ID: 6894697
[TBL] [Abstract][Full Text] [Related]
59. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.
Dowlati A; Lazarus HM; Hartman P; Jacobberger JW; Whitacre C; Gerson SL; Ksenich P; Cooper BW; Frisa PS; Gottlieb M; Murgo AJ; Remick SC
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5929-35. PubMed ID: 14676117
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics and fate of 3H-trospectomycin sulphate, a novel aminocyclitol antibiotic, in male and female rats.
Nichols DJ; Burrows M; Bye A; Constable DA; Dring LG; Jeffrey P
Xenobiotica; 1991 Jul; 21(7):827-37. PubMed ID: 1837966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
